Zacks Research Weighs in on Catalyst Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Investment analysts at Zacks Research raised their Q1 2025 earnings estimates for Catalyst Pharmaceuticals in a note issued to investors on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $0.67 per share for the quarter, up from their prior forecast of $0.64. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' Q2 2025 earnings at $0.69 EPS, Q3 2025 earnings at $0.67 EPS and FY2025 earnings at $2.70 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. The company had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million.

A number of other brokerages also recently weighed in on CPRX. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $34.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. HC Wainwright reissued a "buy" rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Bank of America initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They set a "buy" rating and a $23.00 price target for the company. Citigroup initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They set a "buy" rating and a $27.00 price target for the company. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, March 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $26.43.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded up $0.21 during trading on Friday, reaching $14.89. The company had a trading volume of 772,215 shares, compared to its average volume of 1,467,338. Catalyst Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $17.76. The stock has a market cap of $1.76 billion, a PE ratio of 24.07, a PEG ratio of 0.83 and a beta of 0.89. The business's 50 day moving average price is $15.52 and its 200-day moving average price is $14.61.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several large investors have recently bought and sold shares of CPRX. Vanguard Group Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company's stock valued at $119,694,000 after buying an additional 73,930 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Catalyst Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company's stock valued at $43,738,000 after buying an additional 41,923 shares during the period. Boston Partners boosted its holdings in shares of Catalyst Pharmaceuticals by 965.2% in the fourth quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company's stock valued at $25,610,000 after buying an additional 1,396,930 shares during the period. Opaleye Management Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 4.3% in the fourth quarter. Opaleye Management Inc. now owns 1,257,200 shares of the biopharmaceutical company's stock valued at $21,436,000 after buying an additional 52,200 shares during the period. Finally, LSV Asset Management boosted its holdings in shares of Catalyst Pharmaceuticals by 25.6% in the third quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company's stock valued at $14,505,000 after buying an additional 253,100 shares during the period. Institutional investors own 79.22% of the company's stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the sale, the insider now owns 124,433 shares of the company's stock, valued at $2,045,678.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.10% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.